Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing

Journal of Chemotherapy

Volumn 10, Issue 5, 1998, Pages 354-359

  Zhang, J N ^a,b   Liu, X G ^a,c   Zhu, M ^a   Chiu, F C K ^a   Li, R C ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b Cap Univ of Medicinal Sciences   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Autoinduction; Bioavailability; Microbial degradation; Multiple dosing; Presystemic factors; Rifampicin

Indexed keywords

RIFAMPICIN;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RISK FACTOR;

EID: 0031740929     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.5.354     Document Type: Article

References (17)

1. Hegazy I, Khayyal M. Intestinal microsomal enzyme induction by rifampicin. Chemioterapia 1987; 6: 325-327.
2. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 796-801.
3. Rowland IR. Interactions of the gut microflora and the host in toxicology. Toxicol Pathol 1988; 16: 147-153.
4. Hooymans PM, Merkus FW. Current status of cardiac glycoside drug interactions. Clin Pharm 1985; 4: 404-413.
5. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev 1988; 19: 234-261.
6. Ahr HJ, Boberg M, Krause HP, et al. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism, and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneim Forsch/ Drug Res 1989; 39: 1254-1260.
7. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985; 63: 1205-1211.
8. Strolin-Benedetti M, Dostert P. Introduction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994; 102: 101-105.
9. Musch E, Loos U, Schwabe HK. Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide. Pneumologie 1990; 44: 486-487.
10. Li RC, Narang PK, Poggesi I, Strolin-Benedetti M. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos. 17, 223-236 (1996).
11. Strolin-Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990; 20: 1113-1119.
12. Nahata MC, Fan-Havard P, Barson WJ, Bartkowski HM, Kosnik EJ. Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur J Clin Pharmacol 1990; 38: 515-517.
13. Gibaldi M, Perrier E. Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics, 2nd ed (J. Swarbrick, ed.), New York: Marcel Dekker, Inc., 1982: 409-416.
14. Huang R, Okuno H, Takasu M, Shiozaki Y, Inoue K. Comparision of effects of xenobiotics on extrahepatic and hepatic microsomal drug-metabolizing enzymes in mice. Environ Toxicol Pharmacol 1996; 1:123-130.
15. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450 IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90:1871-1878.
16. Anufrieva RG, Zaslavskaia PL, Shenderov BA. Changes in the microbial ecology and morphology of large intestine biofilm in albino rats under the influence of rifampicin. Antibiot Khimioter 1989; 34: 457-462.
17. Mitrokhin SD, Shenderov BA. Microbiological and biochemical indices of changes in microbial ecology of rat large intestine under the effect of rifampicin. Antibiot Khimioter 1989; 34: 448-452.